TipRanks
Cogent Biosciences (COGT)
NASDAQ:COGT
US Market
Want to see COGT full AI Analyst Report?

Cogent Biosciences (COGT) Stock Forecast & Price Target

738 Followers
See the Price Targets and Ratings of:

COGT Analyst Ratings

Strong Buy
8Ratings
Strong Buy
7 Buy
1 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Cogent
Biosciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

COGT Stock 12 Month Forecast

Average Price Target

$56.29
▲(52.95% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Cogent Biosciences in the last 3 months. The average price target is $56.29 with a high forecast of $62.00 and a low forecast of $52.00. The average price target represents a 52.95% change from the last price of $36.80.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","38":"$38","63":"$63","25.5":"$25.5","50.5":"$50.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":62,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$62.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":56.285714285714285,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$56.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":52,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$52.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,25.5,38,50.5,63],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.59,33.92923076923077,36.26846153846154,38.60769230769231,40.94692307692308,43.28615384615385,45.62538461538462,47.964615384615385,50.30384615384615,52.643076923076926,54.9823076923077,57.321538461538466,59.66076923076923,{"y":62,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.59,33.48967032967033,35.38934065934066,37.28901098901099,39.18868131868132,41.08835164835165,42.988021978021976,44.887692307692305,46.787362637362634,48.68703296703296,50.58670329670329,52.48637362637363,54.386043956043956,{"y":56.285714285714285,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.59,33.16,34.73,36.3,37.87,39.44,41.01,42.58,44.15,45.72,47.29,48.86,50.43,{"y":52,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.13,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.76,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.52,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.96,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.89,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.24,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.63,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.81,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.48,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.93,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.68,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.59,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$62.00Average Price Target$56.29Lowest Price Target$52.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS
$60
Buy
63.04%
Upside
Reiterated
10/13/26
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (NASDAQ: BEAM), Cogent Biosciences (NASDAQ: COGT) and InMode (NASDAQ: INMD)
Guggenheim Analyst forecast on COGT
Guggenheim
Guggenheim
$52
Buy
41.30%
Upside
Reiterated
10/06/26
Guggenheim Remains a Buy on Cogent Biosciences (COGT)
H.C. Wainwright Analyst forecast on COGT
H.C. Wainwright
H.C. Wainwright
$55
Buy
49.46%
Upside
Reiterated
09/16/26
Analysts' Top Healthcare Picks: GeoVax Labs (GOVX), Cogent Biosciences (COGT)
Wedbush
$55
Buy
49.46%
Upside
Reiterated
09/16/26
Analysts Are Bullish on These Healthcare Stocks: Maravai Lifesciences Holdings (MRVI), Thermo Fisher (TMO)
LifeSci Capital Analyst forecast on COGT
LifeSci Capital
LifeSci Capital
$55
Buy
49.46%
Upside
Reiterated
09/15/26
Cogent Biosciences Earns Buy Rating as Bezuclasnib Advances Toward 2027 PDUFA and Multiple 2026 Catalysts; $55 Price Target Reaffirmed
J.P. Morgan Analyst forecast on COGT
J.P. Morgan
J.P. Morgan
$62
Buy
68.48%
Upside
Reiterated
09/09/26
Cogent Biosciences added to Analyst Focus List at JPMorganCogent Biosciences added to Analyst Focus List at JPMorgan
Piper Sandler Analyst forecast on COGT
Piper Sandler
Piper Sandler
$52→$55
Buy
49.46%
Upside
Reiterated
08/17/26
Cogent Biosciences price target raised to $55 from $52 at Piper SandlerCogent Biosciences price target raised to $55 from $52 at Piper Sandler
Needham Analyst forecast on COGT
Needham
Needham
―
Hold
―
Assigned
08/11/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Tenax Therapeutics (NASDAQ: TENX) and Cogent Biosciences (NASDAQ: COGT)
Stifel Nicolaus Analyst forecast on COGT
Stifel Nicolaus
Stifel Nicolaus
$45
Buy
22.28%
Upside
Reiterated
06/15/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Jefferies
$55
Buy
49.46%
Upside
Initiated
03/16/26
Cogent Biosciences assumed with a Buy at JefferiesCogent Biosciences assumed with a Buy at Jefferies
Robert W. Baird Analyst forecast on COGT
Robert W. Baird
Robert W. Baird
$34→$35
Hold
-4.89%
Downside
Reiterated
02/19/26
Cogent Biosciences price target raised to $35 from $34 at BairdCogent Biosciences price target raised to $35 from $34 at Baird
Raymond James Analyst forecast on COGT
Raymond James
Raymond James
$60
Buy
63.04%
Upside
Reiterated
01/26/26
Raymond James Reaffirms Their Buy Rating on Cogent Biosciences (COGT)
Leerink Partners Analyst forecast on COGT
Leerink Partners
Leerink Partners
$18→$50
Buy
35.87%
Upside
Assigned
11/10/25
Cogent Biosciences price target raised to $50 from $18 at LeerinkCogent Biosciences price target raised to $50 from $18 at Leerink
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS
$60
Buy
63.04%
Upside
Reiterated
10/13/26
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (NASDAQ: BEAM), Cogent Biosciences (NASDAQ: COGT) and InMode (NASDAQ: INMD)
Guggenheim Analyst forecast on COGT
Guggenheim
Guggenheim
$52
Buy
41.30%
Upside
Reiterated
10/06/26
Guggenheim Remains a Buy on Cogent Biosciences (COGT)
H.C. Wainwright Analyst forecast on COGT
H.C. Wainwright
H.C. Wainwright
$55
Buy
49.46%
Upside
Reiterated
09/16/26
Analysts' Top Healthcare Picks: GeoVax Labs (GOVX), Cogent Biosciences (COGT)
Wedbush
$55
Buy
49.46%
Upside
Reiterated
09/16/26
Analysts Are Bullish on These Healthcare Stocks: Maravai Lifesciences Holdings (MRVI), Thermo Fisher (TMO)
LifeSci Capital Analyst forecast on COGT
LifeSci Capital
LifeSci Capital
$55
Buy
49.46%
Upside
Reiterated
09/15/26
Cogent Biosciences Earns Buy Rating as Bezuclasnib Advances Toward 2027 PDUFA and Multiple 2026 Catalysts; $55 Price Target Reaffirmed
J.P. Morgan Analyst forecast on COGT
J.P. Morgan
J.P. Morgan
$62
Buy
68.48%
Upside
Reiterated
09/09/26
Cogent Biosciences added to Analyst Focus List at JPMorganCogent Biosciences added to Analyst Focus List at JPMorgan
Piper Sandler Analyst forecast on COGT
Piper Sandler
Piper Sandler
$52→$55
Buy
49.46%
Upside
Reiterated
08/17/26
Cogent Biosciences price target raised to $55 from $52 at Piper SandlerCogent Biosciences price target raised to $55 from $52 at Piper Sandler
Needham Analyst forecast on COGT
Needham
Needham
―
Hold
―
Assigned
08/11/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Tenax Therapeutics (NASDAQ: TENX) and Cogent Biosciences (NASDAQ: COGT)
Stifel Nicolaus Analyst forecast on COGT
Stifel Nicolaus
Stifel Nicolaus
$45
Buy
22.28%
Upside
Reiterated
06/15/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Jefferies
$55
Buy
49.46%
Upside
Initiated
03/16/26
Cogent Biosciences assumed with a Buy at JefferiesCogent Biosciences assumed with a Buy at Jefferies
Robert W. Baird Analyst forecast on COGT
Robert W. Baird
Robert W. Baird
$34→$35
Hold
-4.89%
Downside
Reiterated
02/19/26
Cogent Biosciences price target raised to $35 from $34 at BairdCogent Biosciences price target raised to $35 from $34 at Baird
Raymond James Analyst forecast on COGT
Raymond James
Raymond James
$60
Buy
63.04%
Upside
Reiterated
01/26/26
Raymond James Reaffirms Their Buy Rating on Cogent Biosciences (COGT)
Leerink Partners Analyst forecast on COGT
Leerink Partners
Leerink Partners
$18→$50
Buy
35.87%
Upside
Assigned
11/10/25
Cogent Biosciences price target raised to $50 from $18 at LeerinkCogent Biosciences price target raised to $50 from $18 at Leerink
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
OVIDOvid Therapeutics
AXGNAxoGen
PTGXProtagonist Therapeutics
ESTAEstablishment Labs Holdings
REPLReplimune Group
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cogent Biosciences

3 Months
Anupam RamaJ.P. Morgan
Success Rate
8/15 ratings generated profit
53%
Average Return
+21.83%
Copying Anupam Rama's trades and holding each position for 3 Months would result in 53.33% of your transactions generating a profit, with an average return of +21.83% per trade.
1 Year
Anupam RamaJ.P. Morgan
Success Rate
9/15 ratings generated profit
60%
Average Return
+144.57%
Copying Anupam Rama's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +144.57% per trade.
2 Years
Anupam RamaJ.P. Morgan
Success Rate
10/15 ratings generated profit
67%
Average Return
+177.29%
Copying Anupam Rama's trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +177.29% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

COGT Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
9
8
3
4
6
Buy
7
5
7
5
5
Hold
1
1
1
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
14
11
10
12
In the current month, COGT has received 11 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. COGT average Analyst price target in the past 3 months is 56.29.
Each month's total comprises the sum of three months' worth of ratings.

COGT Financial Forecast

COGT Earnings Forecast

Next quarter’s earnings estimate for COGT is -$0.56 with a range of -$0.64 to -$0.43. The previous quarter’s EPS was -$0.52. COGT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year COGT has Performed in-line its overall industry.
Next quarter’s earnings estimate for COGT is -$0.56 with a range of -$0.64 to -$0.43. The previous quarter’s EPS was -$0.52. COGT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year COGT has Performed in-line its overall industry.

COGT Sales Forecast

Next quarter’s sales forecast for COGT is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. COGT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year COGT has Performed in-line its overall industry.
Next quarter’s sales forecast for COGT is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. COGT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year COGT has Performed in-line its overall industry.

COGT Stock Forecast FAQ

What is COGT’s average 12-month price target, according to analysts?
Based on analyst ratings, Cogent Biosciences’s 12-month average price target is 56.29.
    What is COGT’s upside potential, based on the analysts’ average price target?
    Cogent Biosciences has 52.95% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is COGT a Buy, Sell or Hold?
          Cogent Biosciences has a consensus rating of Strong Buy which is based on 7 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Cogent Biosciences’s price target?
            The average price target for Cogent Biosciences is 56.29. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $62.00 ,the lowest forecast is $52.00. The average price target represents 52.95% Increase from the current price of $36.8.
              What do analysts say about Cogent Biosciences?
              Cogent Biosciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of COGT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.